Tirzepatide and Smoking: What Studies Report

People searching "can you smoke while on tirzepatide" are usually asking whether tobacco or nicotine changes how the drug behaves, or whether the drug changes anything about smoking. This page does not answer that as a personal question. It summarises what the published, peer-reviewed literature on tirzepatide actually contains on the topic, what its pharmacology would and would not predict, and where the evidence is simply missing. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, health condition, or treatment decision.

The short version of the evidence

Across the verified tirzepatide literature reviewed here — phase 3 trials in type 2 diabetes, obesity trials, a steatohepatitis trial, a paediatric trial, receptor pharmacology work, and systematic reviews — no study was identified that specifically enrolled smokers versus non-smokers as a comparison, co-administered nicotine, or measured tobacco-smoke effects on tirzepatide exposure. Smoking is not a reported endpoint, subgroup, or safety signal in any of the cited papers.

That absence is itself the finding. Statements circulating online that smoking "blocks" tirzepatide, or that tirzepatide reduces nicotine craving, are not supported by the trials summarised below. They may derive from adjacent literature on other incretin drugs, but they are not what these tirzepatide papers reported.

What tirzepatide is, pharmacologically

Tirzepatide was characterised in cell and receptor work as a single peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Researchers described it as an imbalanced and biased dual agonist, reporting greater relative activity at the GIP receptor than at the GLP-1 receptor, and biased signalling at GLP-1 receptors that favoured cAMP generation over β-arrestin recruitment. That receptor profile is the mechanistic starting point for any interaction question.

A drug-class summary described tirzepatide as a once-weekly subcutaneous injectable approved for glycaemic control in type 2 diabetes, summarising its pharmacology, administration route, and reported adverse-effect pattern. A broader systematic update characterised tirzepatide's structure as a 39-amino-acid synthetic peptide with fatty-acid modification supporting weekly dosing, and reviewed its metabolic effects across the development programme.

Why peptide metabolism matters to the smoking question

The best-documented pharmacokinetic interaction involving tobacco smoke is induction of hepatic cytochrome P450 1A2 by polycyclic aromatic hydrocarbons in smoke, which lowers plasma concentrations of certain CYP1A2 substrates. Tirzepatide, as described in the systematic update and the drug monograph summary, is a modified peptide cleared by proteolytic catabolism rather than a small molecule dependent on CYP1A2 oxidation. On mechanism alone, the classic smoke–CYP1A2 route would not be predicted to apply. No verified paper in this list tested that prediction directly, so it remains a mechanistic inference rather than a measured result.

A second, indirect pharmacokinetic consideration is gastric emptying. Incretin receptor agonism slows gastric emptying, and that is part of why appetite and food intake change. A mechanistic study in people with type 2 diabetes reported reductions in appetite, energy intake, and fat mass with tirzepatide. Where oral drugs are involved, altered gastric emptying is the interaction pathway that pharmacologists discuss — not inhaled nicotine, which bypasses the gut entirely.

What the trials reported about efficacy (context, not interaction)

Understanding the interaction question requires knowing what the trials measured. The table below summarises the design focus of the verified studies. None listed smoking as an endpoint.

A network meta-analysis of randomised controlled trials compared subcutaneous tirzepatide with semaglutide in adults with type 2 diabetes, pooling glycaemic and body-weight outcomes across trials. Again, smoking status was not a reported moderator in the published abstract scope.

Adverse Events and Smoking: What Studies Report

The adverse-event pattern most consistently reported across the tirzepatide programme was gastrointestinal. The SURPASS-1 investigators reported nausea, diarrhoea, and vomiting as the most common adverse events, generally mild to moderate and most frequent during dose escalation. The SURPASS-5 trial similarly reported gastrointestinal events as the predominant adverse-event category, and the paediatric SURPASS-PEDS trial reported a safety profile consistent with adult experience.

None of these reports attributed any adverse event to smoking, and none stratified nausea or vomiting rates by tobacco use. Nicotine independently has well-described emetic and gastrointestinal effects in pharmacology textbooks, and both nicotine and incretin agonists act on pathways involving the area postrema — but no verified tirzepatide study measured whether those effects are additive. That is a plausible mechanistic overlap with no trial data behind it, and it should be read as a hypothesis, not a finding.

Cardiovascular and respiratory context

Smoking is an established cardiovascular and respiratory risk factor independent of any medication. The verified tirzepatide papers reported metabolic endpoints — glycaemic control, body weight, hepatic histology — rather than smoking-related cardiovascular outcomes. The steatohepatitis trial and the review of tirzepatide for overweight and obesity management discussed cardiometabolic risk in the context of weight and liver disease, not tobacco exposure.

Does tirzepatide affect nicotine craving? What the verified literature shows

There is public interest in whether incretin drugs affect addictive behaviours, driven partly by the observation that GLP-1 receptors are expressed in brain regions involved in reward. Within the verified list used for this page, no study measured smoking cessation, cigarette consumption, nicotine craving, or nicotine self-administration.

What was measured was appetite and eating behaviour. The mechanistic study in type 2 diabetes reported that tirzepatide reduced appetite and energy intake alongside reductions in fat mass. A review of tirzepatide in overweight and obesity summarised its weight-management pharmacology and clinical trial results. Extending appetite findings to nicotine reward is an extrapolation across behaviours, species of evidence, and receptor systems. The literature summarised here does not support it in either direction.

How researchers would test a smoking interaction, if they did

Reading the gap precisely helps. A study capable of answering the question would need at least one of the following designs, none of which appears in the verified papers:

• Pharmacokinetic comparison: tirzepatide plasma exposure measured in smokers versus non-smokers at matched doses, to detect any change in absorption or clearance.
• Prespecified subgroup analysis: efficacy and adverse-event rates in trial participants stratified by baseline smoking status, which the abstracts of the SURPASS-1 and SURMOUNT-4 reports did not present.
• Behavioural endpoint trial: cigarettes per day or biochemically verified abstinence as a primary or secondary outcome.
• Preclinical reward-pathway work: nicotine self-administration models with dual GIP/GLP-1 receptor agonism, informed by the receptor-bias findings reported in the cell pharmacology study.

Until such work is published and peer reviewed, the honest statement is that the interaction is uncharacterised.

Regulatory and research-use context

Tirzepatide is an approved prescription medicine in multiple jurisdictions for indications described in the clinical literature, including type 2 diabetes glycaemic control as summarised in the drug monograph review and weight management as reviewed in the obesity pharmacotherapy article. Peptides labelled "research use only" are not approved for human administration, and prescribing information — not web summaries — is the document that carries formal interaction listings. Anyone weighing tobacco use alongside a prescribed medicine is in a clinical conversation, not an informational one.

Summary of what is known and unknown

• Known: tirzepatide is a dual GIP/GLP-1 receptor agonist with biased signalling (PMID 32730231).
• Known: gastrointestinal adverse events dominated the reported safety profile across phase 3 trials (SURPASS-1) (SURPASS-5).
• Known: appetite and energy intake reductions were measured directly (PMID 36857477).
• Unknown: whether smoking alters tirzepatide exposure, tolerability, or efficacy.
• Unknown: whether tirzepatide influences nicotine craving or smoking behaviour.

This page describes published research and does not recommend, endorse, or discourage any use of any substance. It is for educational purposes only and is not medical advice; consult a licensed physician.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (JAMA, 2022)
• Tirzepatide: A Systematic Update (International Journal of Molecular Sciences, 2022)
• New Drug: Tirzepatide (Mounjaro) (The Senior Care Pharmacist, 2023)
• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes (Diabetes Care, 2023)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)
• Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (Diabetologia, 2024)
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (New England Journal of Medicine, 2024)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (New England Journal of Medicine, 2025)
• Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial (Lancet, 2025)